Condition
Incretins
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
60.0%-27% vs avg
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
60.0%
-26.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
60% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 3 (1)
P 4 (1)
Trial Status
Completed3
Terminated2
Trial Success Rate
60.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05767177Not ApplicableCompleted
Jejunal Ketogenesis and Type 2 Diabetes
NCT03966261TerminatedPrimary
The Role of Incretins in Bone Remodeling in Humans
NCT05857085Phase 4Completed
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
NCT05030376Not ApplicableCompletedPrimary
Intraileal Glucose vs. Saline Infusion on Hormone Secretion and Glycemic Excursions
NCT04371978Phase 3Terminated
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Showing all 5 trials